Journal: Frontiers in Cell and Developmental Biology

Article Title: Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR

doi: 10.3389/fcell.2021.710721

Figure Lengend Snippet: EGFR might participate in PDT reversing cholangiocarcinoma gemcitabine resistance. RBE or gemcitabine-resistant RBE-R cells were treated or non-treated with PDT and examined for EGFR mRNA expression by real-time qPCR (A) and the protein levels of EGFR by Immunoblotting (B) . (C) EGFR overexpression was achieved in RBE-R cells by transfecting EGFR-overexpressing vector (EGFR). The transfection efficiency was verified using real-time qPCR. Then, RBE-R cells were transfected with EGFR or empty vector (negative control), exposed to PDT treatment, and examined for cell viability by MTT assay (D) ; cell apoptosis by Flow cytometry (E) ; cell cycle distribution by Flow cytometry (F) ; the protein levels of EGFR, Erk1/2, p-Erk1/2, Akt, p-Akt, and VEGF by Immunoblotting (G) . * P < 0.05, ** P < 0.01, # P < 0.05, ## P < 0.01.

Article Snippet: The following antibodies were used: anti-ki67 (27309-1-AP; Proteintech, Wuhan, China), anti-Cyclin D1 (60186-1-Ig, Proteintech), anti-cleaved-caspase 3 (ab2302; Abcam, Cambridge, MA, United States), anti-caspase 3 (19677-1-AP, Proteintech), anti-EGFR (CSB-PA10279A0Rb; CUSABIO, Houston, TX, United States), Erk1/2 (67170-1-Ig, Proteintech), p-Erk1/2 (sc-81492; Santa Cruz, Dallas, TX, United States), anti-Akt (Y409094; ABM, Richmond, BC, Canada), anti-p-Akt (Y011054, ABM), anti-VEGF (CSB-PA07529A0Rb, CUSABIO), anti-KLF10 (ab73537, Abcam), and anti-GAPDH (ab8245, Abcam).

Techniques: Expressing, Western Blot, Over Expression, Plasmid Preparation, Transfection, Negative Control, MTT Assay, Flow Cytometry

Journal: Frontiers in Cell and Developmental Biology

Article Title: Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR

doi: 10.3389/fcell.2021.710721

Figure Lengend Snippet: KLF10 silencing attenuates the effects of PDT on gemcitabine-resistant cells. RBE-R cells were transfected with si-KLF10 or si-NC (negative control), exposed to PDT treatment, and examined for the cell viability by MTT assay (A) ; cell apoptosis by Flow cytometry (B) ; cell cycle distribution by Flow cytometry (C) ; the protein levels of KLF10, EGFR, p-Erk1/2, Erk1/2, p-Akt, Akt, and VEGF by Immunoblotting (D) . * P < 0.05, ** P < 0.01.

Article Snippet: The following antibodies were used: anti-ki67 (27309-1-AP; Proteintech, Wuhan, China), anti-Cyclin D1 (60186-1-Ig, Proteintech), anti-cleaved-caspase 3 (ab2302; Abcam, Cambridge, MA, United States), anti-caspase 3 (19677-1-AP, Proteintech), anti-EGFR (CSB-PA10279A0Rb; CUSABIO, Houston, TX, United States), Erk1/2 (67170-1-Ig, Proteintech), p-Erk1/2 (sc-81492; Santa Cruz, Dallas, TX, United States), anti-Akt (Y409094; ABM, Richmond, BC, Canada), anti-p-Akt (Y011054, ABM), anti-VEGF (CSB-PA07529A0Rb, CUSABIO), anti-KLF10 (ab73537, Abcam), and anti-GAPDH (ab8245, Abcam).

Techniques: Transfection, Negative Control, MTT Assay, Flow Cytometry, Western Blot

Journal: Frontiers in Cell and Developmental Biology

Article Title: Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR

doi: 10.3389/fcell.2021.710721

Figure Lengend Snippet: KLF10 modulates PDT reversing cholangiocarcinoma gemcitabine resistance through EGFR. RBE-R cells were co-transfected with si-KLF10 and si-EGFR, exposed to PDT treatment, and examined for the mRNA expression of KLF10 (A) and EGFR (B) by real-time qPCR; cell viability by MTT assay (C) ; cell apoptosis by Flow cytometry (D) ; cell cycle distribution by Flow cytometry (E) ; the protein levels of KLF10, EGFR, p-Erk1/2, Erk1/2, p-Akt, Akt, and VEGF by Immunoblotting (F) . * P < 0.05, ** P < 0.01, compared with the si-NC1 + si-NC2 group; ## P < 0.01, compared with the si-KLF10 + si-NC2 group.

Article Snippet: The following antibodies were used: anti-ki67 (27309-1-AP; Proteintech, Wuhan, China), anti-Cyclin D1 (60186-1-Ig, Proteintech), anti-cleaved-caspase 3 (ab2302; Abcam, Cambridge, MA, United States), anti-caspase 3 (19677-1-AP, Proteintech), anti-EGFR (CSB-PA10279A0Rb; CUSABIO, Houston, TX, United States), Erk1/2 (67170-1-Ig, Proteintech), p-Erk1/2 (sc-81492; Santa Cruz, Dallas, TX, United States), anti-Akt (Y409094; ABM, Richmond, BC, Canada), anti-p-Akt (Y011054, ABM), anti-VEGF (CSB-PA07529A0Rb, CUSABIO), anti-KLF10 (ab73537, Abcam), and anti-GAPDH (ab8245, Abcam).

Techniques: Transfection, Expressing, MTT Assay, Flow Cytometry, Western Blot

Journal: Cancers

Article Title: Analysis of the Single-Cell Heterogeneity of Adenocarcinoma Cell Lines and the Investigation of Intratumor Heterogeneity Reveals the Expression of Transmembrane Protein 45A (TMEM45A) in Lung Adenocarcinoma Cancer Patients

doi: 10.3390/cancers14010144

Figure Lengend Snippet: Antibodies used for mass cytometry.

Article Snippet: 3170009B , Fluidigm , EGFR , 170 Er.

Techniques: Cytometry

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer

doi: 10.1186/1756-9966-29-6

Figure Lengend Snippet: Differentially expressed candidate imprinted genes, oncogenes and tumor suppressing genes identified by MAS5.0, Array2BIO and BGX methods

Article Snippet: Sections were stained with anti-decorin (SC-73896, Santa Cruz Biotechnology, Inc), anti-EGFR (BA0843, Boster Biological Technology, Ltd, Wuhan, China), anti-cyclin D1 (Cat. #RM-9104-S1, Neomarker Labvision, USA), or anti-PCNA (BM0104, Boster Biological Technology, Ltd, Wuhan, China) antibodies.

Techniques: Protein Binding, Binding Assay, Activity Assay, Migration, Cell Differentiation, Transduction, Activation Assay

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer

doi: 10.1186/1756-9966-29-6

Figure Lengend Snippet: Expression levels of decorin, EGFR, cyclin D1 and PCNA mRNA in mammary glands and spontaneous breast cancer tissues of TA2 mice

Article Snippet: Sections were stained with anti-decorin (SC-73896, Santa Cruz Biotechnology, Inc), anti-EGFR (BA0843, Boster Biological Technology, Ltd, Wuhan, China), anti-cyclin D1 (Cat. #RM-9104-S1, Neomarker Labvision, USA), or anti-PCNA (BM0104, Boster Biological Technology, Ltd, Wuhan, China) antibodies.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models

doi: 10.3389/fonc.2022.818437

Figure Lengend Snippet: List of IMC antibodies.

Article Snippet: 142 Nd , EGFR , D38B1 , 3142013D , Fluidigm , 1:50.

Techniques: